To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: HEADACHE MEETING: New Data Confirm Rapid Onset of Action With Zomig For Migraine URL: http://www.pslgroup.com/dg/10C93A.htm Doctor's Guide June 25, 1999
BARCELONA, SPAIN -- June 25, 1999 -- Data from a new study comparing two of the newer 'triptans', Zomig™ (zolmitriptan, AstraZeneca) 2.5mg and rizatriptan 10mg, in the acute treatment of migraine, showed that they were indistinguishable in terms of time to pain free - the primary end-point of this trial.1 The study, presented at the 9th International Headache Society's Congress in Barcelona, Spain, confirmed the rapid and high efficacy of Zomig 2.5mg.
Although an adjusted sub-group analysis had been used to claim that there was a significant difference between Zomig and rizatriptan, during the presentation of the data it was confirmed that when all patients were considered there was no significant difference between the two treatments in terms of time to pain free.
Dr. Alan Rapoport, Director of The New England Headache Center, Stamford, CT, re-affirmed that "Zomig provides the complete triptan profile: rapid, reliable, long-lasting, well-tolerated relief of migraine headache."
Related Link: Zomig --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.